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Definition of the disease: Dominant Optic Atrophy (DOA) is a neuro-ophthalmic condition characterized by a
bilateral degeneration of the optic nerves, causing insidious visual loss, typically starting during the first decade of
life. The disease affects primary the retinal ganglion cells (RGC) and their axons forming the optic nerve, which
transfer the visual information from the photoreceptors to the lateral geniculus in the brain.
Epidemiology: The prevalence of the disease varies from 1/10000 in Denmark due to a founder effect, to 1/30000
in the rest of the world.
Clinical description: DOA patients usually suffer of moderate visual loss, associated with central or paracentral
visual field deficits and color vision defects. The severity of the disease is highly variable, the visual acuity ranging
from normal to legal blindness. The ophthalmic examination discloses on fundoscopy isolated optic disc pallor or
atrophy, related to the RGC death. About 20% of DOA patients harbour extraocular multi-systemic features,
including neurosensory hearing loss, or less commonly chronic progressive external ophthalmoplegia, myopathy,
peripheral neuropathy, multiple sclerosis-like illness, spastic paraplegia or cataracts.
Aetiology: Two genes (OPA1, OPA3) encoding inner mitochondrial membrane proteins and three loci (OPA4, OPA5,
OPA8) are currently known for DOA. Additional loci and genes (OPA2, OPA6 and OPA7) are responsible for X-linked
or recessive optic atrophy. All OPA genes yet identified encode mitochondrial proteins embedded in the inner
membrane and ubiquitously expressed, as are the proteins mutated in the Leber Hereditary Optic Neuropathy.
OPA1 mutations affect mitochondrial fusion, energy metabolism, control of apoptosis, calcium clearance and
maintenance of mitochondrial genome integrity. OPA3 mutations only affect the energy metabolism and the
control of apoptosis.
Diagnosis: Patients are usually diagnosed during their early childhood, because of bilateral, mild, otherwise
unexplained visual loss related to optic discs pallor or atrophy, and typically occurring in the context of a family
history of DOA. Optical Coherence Tomography further discloses non-specific thinning of retinal nerve fiber layer,
but a normal morphology of the photoreceptors layers. Abnormal visual evoked potentials and pattern ERG may
also reflect the dysfunction of the RGCs and their axons. Molecular diagnosis is provided by the identification of a
mutation in the OPA1 gene (75% of DOA patients) or in the OPA3 gene (1% of patients).
Prognosis: Visual loss in DOA may progress during puberty until adulthood, with very slow subsequent chronic
progression in most of the cases. On the opposite, in DOA patients with associated extra-ocular features, the visual
loss may be more severe over time.
Management: To date, there is no preventative or curative treatment in DOA; severely visually impaired patients
may benefit from low vision aids. Genetic counseling is commonly offered and patients are advised to avoid
alcohol and tobacco consumption, as well as the use of medications that may interfere with mitochondrial
metabolism. Gene and pharmacological therapies for DOA are currently under investigation.* Correspondence: guy.lenaers@inserm.fr
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Disease name/synonyms
DOA: Dominant Optic Atrophy (OMIM #165500), ini-
tially called Kjer’s Optic Atrophy, was first described by
the Danish ophthalmologist Dr. Poul Kjer [1]. DOA
is also called Autosomal Dominant Optic Atrophy
(ADOA), to emphasize its autosomal mode of inheritance,
in contrast with Leber Hereditary Optic Neuropathy
(LHON), inherited by mutations on the mitochondrial
genome and maternal lineage.
DOAD-DOAplus: Dominant Optic Atrophy and Deaf-
ness and DOAplus (both OMIM #125250) are syndromic
forms of DOA associating neurosensory deafness (DOAD)
and/or other clinical manifestations (DOAplus) like myop-
athy, progressive external ophthalmoplegia, peripheral
neuropathy, stroke, multiple sclerosis or spastic paraplegia.
DOAC: Dominant Optic Atrophy and Cataract
(OMIM #606580) is a rare form of DOA associated to
cataract.
Orphanet reference numbers are ORPHA98673 for
DOA, and ORPHA1215 for DOAplus.
Definition
DOA is an optic neuropathy due to the degeneration of
optic nerve fibers. It belongs to the group of inherited
optic neuropathies (ION), which are genetic conditions
affecting the retinal ganglion cells (RGCs) whose axons
form the optic nerve. Because RGCs are neurons origin-
ating from an extension of the diencephalon, DOA is a
disease of the central nervous system [2].
DOA is a mitochondriopathy, as the genes respon-
sible for DOA encode proteins ubiquitously expressed,
imported into the mitochondria and associated to
the inner membrane [3]. As such, DOA may be syn-
dromic and include extra-ocular symptoms, mostly
neuro-muscular, that are frequently found in mito-
chondriopathies [4].
Epidemiology
DOA is a relatively common form of inherited optic
neuropathy. Its prevalence is 3/100,000 in most popula-
tions in the world, but can reach 1/10,000 in Denmark
where a founder effect was identified [5, 6]. DOA pene-
trance is around 70%, but depending on families,
mutations and study criteria [6,7], it can vary from 100%
[5] to 43% [8]. Syndromic DOAD and DOAplus ac-
count for some 20% of all DOA cases and are fully
penetrant [9].
Clinical description
The disease was first described at the end of the 19th
century [10,11]. Large families were then reported in UK
[12], USA [13] and France [14], but it was after the re-
port of 19 DOA families by the Danish ophthalmologistKjer that this clinical entity was recognized and assigned
his name [1].
Non syndromic dominant optic atrophy
In most cases, DOA presents as a non syndromic, bilat-
eral optic neuropathy. Although DOA is usually diag-
nosed in school-aged children complaining of reading
problems, the condition can manifest later, during adult
life [15-17]. DOA patients typically experience a slowly
progressive, insidious decrease of vision, which can
rarely be asymmetric, although rapid decline has also
been reported in adults [18,19]. The visual impairment
is irreversible, usually moderate (visual acuity: 6/10 to 2/
10) and highly variable between and within families.
However, extreme severity (legal blindness) or very mild
presentation (subclinical decrease in visual acuity) can
be encountered [20,21].
On fundus examination, the optic disk typically pre-
sents a bilateral and symmetrical pallor of its temporal
side, witnessing the loss of RGC fibers entering the optic
nerve (Figure 1A). The optic nerve rim is atrophic and a
temporal grey crescent is often present. Optic disc exca-
vation is not unusual, but its clinical features vary in
most of the cases from that of glaucoma. Optical Coher-
ence Tomography (OCT) discloses the reduction of the
thickness of the peripapillary retinal nerve fiber layer
in all four quadrants, but does not disclose alteration
of other retinal layers [22,23] (Figure 1B). The visual
field typically shows a caecocentral scotoma, and less
frequently a central or paracentral scotoma, while
peripheral visual field remains normal (Figure 1C).
Importantly, there is a specific tritanopia, i.e. a blue-
yellow axis of color confusion, which, when found, is
strongly indicative of Kjer disease [24,25] (Figure 1D).
However, in severe cases or in patients with congeni-
tal dyschromatopsia (daltonism), interpretation of the
color vision defect may be more difficult. The pupillary re-
flex and circadian rhythms are not affected, suggesting
that the melanopsin RGC are spared during the course of
the disease [26,27].
Some patients harboring the pathogenic OPA1 muta-
tion can be asymptomatic; at the opposite end of the
clinical variability spectrum, mutations of the OPA1 gene
have been reported to enhance multisystemic deficits
while sparing totally the optic nerve.
Anterior and/or posterior blue-dot cerulean cata-
ract occurs in the rare DOA patients with an OPA3
mutation [28].
Although typical DOA is associated with a progressive
and irreversible loss of vision, we reported the case of a
young man (23 years) who developed an isolated, pro-
gressive, painless bilateral optic neuropathy as a result of
central scotomas that spontaneously recovered partial vi-
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Figure 1 (See legend on next page.)
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Figure 1 Ophthalmological description of a DOA patient. Results from ophthalmological examination of a paradigm Dominant Optic Atrophy
patient with the c.2708delTTAG mutation in OPA1 (Right) compared to a control patient (Left). (A): Eye fundus examination showing the pallor of
the optic nerve in the DOA patient, in particular on the temporal side, whereas the rest of the retina appears totally unaffected. (B): Optical
Coherence Tomography measures of the retinal nerve fiber layer thickness (black line), at the emergence of the optic disc. In a DOA patient,
there is a general reduction in all quadrants, prevailing on the temporal side, compared to a control patient. (C): Visual field examination
disclosing the caeco-central scotoma in the DOA patient, whereas only the blind spot is detected in control patient. (D): Results from a
desaturated 15-Hue test presenting the characteristic tritanopia (blue-yellow axis) dyschromatopsia defect in the DOA patient.
Table 1 DOA loci and genes
Locus Chromosome Gene Mode of inheritance
OPA1 3q28-29 OPA1 dom.
OPA2 Xp11.4-p11.21 ? X-link
OPA3 19q13.2-q13.3 OPA3 dom./ress.
OPA4 18q12.2-q12.3 ? dom.
OPA5 22q12.1-q13.1 ? dom.
OPA6 8q21-q22 ? ress.
OPA7 11q14.1-q21 TMEM126A ress.
OPA8 16q21-q22 ? dom.
legend: dom: dominant; ress: recessive.
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which was the first mutation to be described in one of
the three alternative OPA1 exons [29]. In addition, we
identified another original case presenting a late onset
(62 years) sequencial and acute loss of vision, associated
to a novel dominant mutation (c.2794C>T) in OPA1
[30], suggesting that atypical natural histories of DOA
can be related to OPA1 mutations.
Syndromic dominant optic atrophy
Syndromic DOAD and DOAplus patients experience full
penetrance and usually more severe visual deficits
[9,31,32].
DOAD and DOAplus with extra-ophthalmological ab-
normalities represent up to 20% of DOA patients with an
OPA1 mutation [6]. The most common extra-ocular sign
in DOA is sensori-neural hearing loss, but other asso-
ciated findings may occur later during life (myopathy and
peripheral neuropathy), suggesting that there is a con-
tinuum of clinical presentations ranging from a mild
“pure DOA” affecting only the optic nerve, to a severe
and multisystemic presentations. Sensori-neural hearing
loss associated to DOA may range from severe and con-
genital to subclinical [31-36] with intra- and inter- familial
variations, and mostly segregate with the OPA1 R445H
(c.1334G>A) mutation. In general, auditory brain stem
responses, which reflect the integrity of the auditory path-
way from the auditory nerve to the inferior colliculus, are
absent, but both ears show normal evoked oto-acoustic
emissions, reflecting the functionality of presynaptic ele-
ments and in particular that of the outer hair cells [37].
Peripheral axonal sensory and/or motor neuropathy
and proximal myopathy may be diagnosed in some DOA
patients from their third decade of life onwards, as well
as a combination of cerebellar and sensory ataxia in
adulthood, multiple sclerosis-like illness and spastic
paraplegia [9,16,38,39]. Progressive external ophthalmo-
plegia is also frequently diagnosed in syndromic DOA-
plus patients [9]. One report of a Behr syndrome
associating DOA to pyramidal signs, ataxia and mental
retardation was linked to an OPA1 mutation [40] and
another report describing a severe neuromuscular
phenotype associated to optic atrophy was described in
two OPA1 compound heterozygote siblings [41]. Musclebiopsy from DOAplus patient revealed features typical of
mitochondrial myopathy, as approximately 5% of all
fibers were deficient in histochemical COX activity and
several fibers showed evidence of subsarcolemmal accu-
mulation of abnormal mitochondria, a phenotype known
as ragged red fibers [9,31,32].
Etiology
Loci and genes
DOA is not genetically highly heterogeneous, in com-
parison with many other ophthalmologic or neurodegen-
erative disorders (Table 1). The first DOA locus, OPA1,
localised on 3q28 was initially considered as unique
[42,43]. But since the discovery of the OPA1 gene in
2000 [44,45], two other loci, OPA4 and OPA5, were fur-
ther identified in few families (1 for OPA4 and 2 for
OPA5) presenting pure DOA [46,47]. Additional loci
and genes were identified as responsible for Optic Atro-
phy, but either with a X-linked mode of inheritance
(OPA2) [48,49], a recessive mode of inheritance (OPA6
and OPA7) [50,51] or as syndromic recessive or domin-
ant forms (OPA3 and OPA8) [28,52,53]. Thus to date,
OPA1 is the major gene responsible for DOA, account-
ing for at least 75% of all the patients, whereas all the
other genes or loci only contribute each for less than 1%
of the patient cohort [7].
Mutations in OPA genes and their consequences on the
mitochondrial physiology
Three genes have been identified to date, OPA1, OPA3 and
TMEM126A (OPA7) (Table 1); all encode mitochondrial
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mitochondrial membrane, due to the presence of at least
one transmembrane domain in their sequence [51,54,55].
In OPA1, 27% of the mutations are missense, 27% are splice
variant, 23.5% lead to frame shift, 16.5% are nonsense
and 6% are deletion or duplication [7]. Most of them
are leading to a haplo-insufficiency situation where
the mutated transcript is degraded by mRNA decay,
thus leading to a reduction of 50% in the amount of
OPA1 protein. As a direct consequence, the different
mutations in OPA1 are not related to the severity of
the disease, and genotype/phenotype correlations are
difficult to infer [25]. In this respect, secondary nu-
clear genes, but not the mitochondrial genome, are
suspected to control the severity of the disease in
non-syndromic patients [56]. Conversely, few missense
mutations in the GTPase domain of OPA1 are re-
sponsible for syndromic cases with severe dominant
negative effects [9], because the mutated protein might
interfere with and inhibit the wild-type protein. Im-
portantly, sporadic cases, cases with de novo mutation
and cases with unknown familial history, account to-
gether for 50% of all patients. Concerning OPA3, in-
direct evidences suggest that the 2 mutations so far
reported in DOAC affect the trans-membrane do-
main, are fully penetrant and act in a dominant nega-
tive manner, as heterozygous carriers of a recessive
mutation leading to the inhibition of OPA3 expression
are asymptomatic [52]. In the case of TMEM126a,
the consanguineous recessive disease is associated to
a mutation introducing a stop codon at position 55,
thus deleting 140 out of the 195 amino-acids composing
the protein [51].
Analysis of OPA1 functions in common cell lines
(HeLa, COS) and dysfunctions in patient fibroblasts
revealed a systematic susceptibility to apoptosis and mild
to severe alteration of the mitochondrial respiration ac-
tivity, essentially associated to a reduced energetic coup-
ling [28,51,57-60]. In addition, the 8 OPA1 isoforms that
result from alternate splicing of 3 exons (4, 4b and 5b)
have discrete functions in structuring the cristae, in
mitochondrial membrane dynamics, maintenance of the
membrane potential, calcium clearance, interaction with
the respiratory chain complexes and maintenance of
mitochondrial genome integrity [61-65]. As a conse-
quence, and as revealed by numerous patient fibroblast
studies, mutations in OPA1 can have a direct although
variable impact on these functions, [31,33,57-59,66], and
possibly the genetic background and aging might con-
tribute to the mitochondrial phenotype, either in a com-
pensatory or in an accentuating manner.
Importantly, the OPA1 gene is the fifth identified nu-
clear gene responsible for generating multiple deletions
in the mitochondrial DNA, together with POLG1 (DNApolymerase γ), PEO1 (twinkle), SLC25A4 (ANT1) and
TP (thymidine phosphorylase). The presence of multiple
deletions in the mtDNA has been found in the skeletal
muscle of the majority of patients harbouring OPA1
mutations, even in those with isolated optic atrophy
[67]. This OPA1 related genomic instability is likely
to play a crucial role in the pathophysiology of DOA,
taken into account its direct functional consequence
on respiratory chain capacities and may explain the
convergence of clinical expressions between DOAplus
syndromes and other disorders related to mutations
in mtDNA.
Optic nerve and animal models
The major concern in studying DOA pathophysiology
concerns the question why RGCs are most specifically
affected by this disease, while the OPA genes are
expressed in all cells of the body. Histochemical studies
revealed a peculiar distribution of mitochondria in ret-
inal ganglion cells. Indeed, they are accumulated in the
cell bodies and in the intra-retinal unmyelinated axons,
where they form varicosities, and are conversely scarce
in the myelinated part of axons after the lamina cribosa
[68-71]. These observations emphasize the importance
of mitochondrial network dynamic in order to maintain
the appropriate intracellular distribution of the mito-
chondria that is critical for axonal and synaptic func-
tions, and point to a possible pathophysiological
mechanism associated to OPA1 that could jeopardize
RGC survival. Alternatively, RGCs are the only neurons
of the body that are exposed to the day long stress of
light, which generates oxidative species favoring the
apoptotic process [72]. Therefore the mitochondrial fra-
gility conferred by OPA1 mutations, together with the
photo-oxidative stress could precipitate RGCs in pre-
mature cell death. A third pathophysiological hypoth-
esis involves the tremendous energetic requirements of
RGCs, as these neurons permanently fire action poten-
tials, in addition through axons that are not myelinated
in the eye globe. As the energetic fuelling of RGCs
soma is restricted in the central part of the retina, due
to the physical constraints imposed by the macula
blood vessel organization, one can hypothesize that due
to the uncoupling of mitochondrial respiration in
OPA1 cells, the ATP synthesis in patient RGCs is lim-
ited and can not fulfill the physiological energetic
requirements for long term cell survival. Which of
these hypotheses represents the princeps mechanism
responsible for the RGC degeneration remains un-
known. Nevertheless, in the last years, two mouse
models with an Opa1 mutation have been generated
and deeply analyzed in terms of vision; both summarize
DOA in that loss of RGCs is preeminent [73,74]. Re-
duction of the scotopic, but not the photopic evoked
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whereas light-adapted ERG and VEP responses revealed
a significant reduction in their amplitudes in another
mouse model [76]. Histological examinations revealed a
decrease of the dentritic length of the RGC-On subpo-
pulation in the retina [77], and abnormal myelin struc-
tures, increase in micro-glia and autophagy were
noticed in the optic nerve [78]. In addition, some mild
neuromuscular symptoms were found, as locomotor ac-
tivity was reduced and tremor observed in old animals,
but no alteration of the audition was detected [79],




Interviewing patients about the natural history of the
disease, at best in the presence of the family, is
mandatory to define the timing of visual loss over time.
Suspicion of DOA prompts also the search of similar
visual signs among relatives. Special attention should be
paid on sensorial or peripheral neuropathy symptoms
that would support the hypothesis of a pathophysiology
related to a mitochondrial deficit. Finding at least one
affected member in two consecutive generations is indi-
cative of a dominant trait, or eventually of a mitochon-
drial maternal transmission, that will further orientate
the genetic investigations.
Ophthalmological examination
DOA is characterized by a bilateral symmetric vision
loss. On funduscopic examination, the cardinal sign
consists in an optic nerve pallor usually bilateral and
symmetric on the temporal side in about 50% of
patients and global in the other 50% [80], especially in
old or severely affected patients. In moderate cases,
the optic nerve atrophy may not be visible. The neu-
roretinal rim is often pale and sometimes associated
with a temporal pigmentary grey crescent. OCT exam-
ination discloses and quantifies the thinning of the
fiber layer in the 4 cardinal directions at the optic
nerve rim [23,81]. Profound papillary excavation is
reported in 21% of eyes from OPA1 patients [82]. Vis-
ual fields examination typically reveals a central, cen-
trocecal or paracentral scotoma, which may be large in
severely affected individuals, and the sparing of the
peripheral visual field [20]. Color vision, evaluated by
the desaturated 15-Hue test discloses often a blue-
yellow loss dyschromatopsy, or tritanopia [25].
Electrophysiological assessment
Visual evoked potentials (VEPs) are typically absent or
delayed, but are not characteristic of the disease. In sub-
clinical or mildly affected patients, no alteration of theVEPs can be found. Pattern electroretinogram (PERG)
shows an abnormal N95:P50 ratio, with reduction in the
amplitude of the N95 waveform suggesting alterations of
the ganglion cells layer [83].
Genetic investigations
The clinical diagnosis of an optic atrophy will orientate
the genetic investigations. After collecting 5ml of blood of
the patient and its relatives and preparing total DNA, the
analysis of OPA1 gene will be performed on the DNA
sample of the index patient by amplifying and sequencing
all the 31 coding exons and their flanking intronic regions.
If a mutation is identified, its segregation in the family
must be analyzed and its identity has to be compared to
the database hosted by the CHU of Angers, France (http://
lbbma.univ-angers.fr/lbbma.php?id=9) to find out if the
mutation is already recognized as pathogenic. If not, the
possible consequence of the mutation on OPA1 transcript
and protein integrity should be analyzed in silico, and by
assessing the expression of the mutated allele by RT-PCR
amplification and sequencing. If no significant mutation is
found in OPA1, then the presence of a deletion in the gene
can be tested with the Multiplex Ligation Probe Amplifi-
cation methodology [84-86]. Otherwise careful reconsider-
ation of the anamnesis might orientate to test either OPA3
gene or the full length mitochondrial genome. If results
are still negative, then when the family is large and many
members are affected, genetic analysis of chromosome
markers can be performed to identify the causative locus
and eventually a novel pathogenic gene. Nevertheless, the
identification of a morbid mutation greatly helps the gen-
etic counseling.
Syndromic cases
Patients with extra-ophthalmological symptoms should be
referred to diagnostic centers specialized in mitochondrial
disorders, in order to obtain additional examinations
by a multidisciplinary team including geneticists, neuro-
ophthalmologists, neurologists, otorhynolaryngologists.
The diagnosis of such multisystemic mitochondrial
disorders often requires the study of the functionality of
the respiratory chain in order to evaluate the severity of
the energetic deficiency. A skeletal muscle biopsy is usu-
ally performed to measure the enzymatic activity of the
5 respiratory complexes and the mitochondrial oxygra-
phy. In addition, it allows anatomo-pathological exami-
nations to check for the presence of mtDNA deletions,
cytochrome c deficient fibers and ragged red fibers. Al-
ternatively, skin fibroblasts are also useful to evaluate
the severity of respiratory chain dysfunction.
Differential diagnosis
The DOA differential diagnosis list includes all the
causes of bilateral optic neuropathies, i.e. compressive,
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toxic, and metabolic optic neuropathies. However, an ap-
propriate clinical and para-clinical work-up, including
neuro-imaging, biochemical studies or genetic tests, will
rule out these causes in most of the cases.
Among these differential diagnosis, normal tension
glaucoma (NTG) may present with signs consistent with
DOA, such as visual field defects and optic disc excava-
tion. However, NTG occurs late during the adulthood
and central visual loss does not occur until late during
the course of the disease. Interestingly, certain allelic se-
quence variants in OPA1 have been found to be more
prevalent in NTG patients in comparison with controls,
thus suggesting some cross-talk between the patho-
physiological mechanisms of these diseases [87].
Other acquired optic neuropathies with similar present-
ing signs as DOA include the nutritional/toxic optic neu-
ropathies, which may have a mitochondrial dysfunction
basis. Among the toxic optic neuropathies, the most com-
mon is the tobacco-alcohol related optic neuropathy.
Other possible agents causing a toxic optic neuropathy in-
clude methylene, ethylene glycol, cyanide, lead, and carbon
monoxide. Finally, certain medications, including etham-
butol, isoniazid, disulfiram can cause a toxic optic atrophy.
Other hereditary optic neuropathies, such as Leber’s
hereditary optic neuropathy, Wolfram’s syndrome or
other neuropathies associated with neurological diseases
(spinocerebellar ataxias, Friedreich’s syndrome, Charcot
Marie-Tooth type 2A, Deafness-Dystonia-Optic Neur-
opathy syndromes etc.) may, at times, present with simi-
lar signs as DOA, though the general context and the
neurological signs help to differentiate those entities.
Differential diagnosis associated to the OPA loci
Athough OPA loci are all primarly associated to optic at-
rophy, in some cases they can be differentiated by the
presence of secondary symptoms (Table 2) that may orient
toward a particular gene or locus. OPA2: Two families
mapping on the OPA2 locus Xp11.4-p11.21 were identi-
fied [48], both presented optic atrophy from early child-
hood [49], and one associated in some instances opticTable 2 Possible symptoms associated to optic atrophy
Locus OpticAtrophy Deafness Poly neuropathy Mu
OPA1 + +/- +\- +\-
OPA2 + - - -
OPA3 + - +\- -
OPA4 + - - -
OPA5 + - - -
OPA6 + - - -
OPA7 + +\- - -
OPA8 + +\- - -
legend: (+): systematic; (+/-): possible; (-): never reported.atrophy to mental retardation and neurological symptoms
as jerks, dysarthria, dysdiadochokinesia, tremor and gait
[88,89]. In both families, only male are affected and female
carriers showed no abnormalities.
OPA3: Patients presenting dominant mutation in
OPA3 gene display an early optic atrophy followed by a
later anterior and/or posterior cortical cataract and dys-
chromatopsy without systematic axis. In some cases,
patients present tremor, extrapyramidal rigidity, pes
cavus and absence of deep tendon reflex [28]. Patients
with OPA3 recessive mutations present the syndromic
Costeff syndrome (see next paragraph).
OPA4 and OPA5: three families linked to the OPA4 or
OPA5 loci present an optic atrophy that can not be dif-
ferentiated from the phenotype observed in OPA1
patients: i.e. optic nerve pallor, decreased visual acuity,
color vision defects, impaired VEP, and normal ERG and
no extra-ocular findings [46,47].
OPA6 and OPA7: Recessive forms of optic atrophy
were described linked to the OPA6 and OPA7 loci.
OPA6 patients present an early onset optic atrophy
slowly progressing with a red-green dyschromatopsia
[50]. Concerning OPA7, a severe juvenile-onset optic at-
rophy with central scotoma was found in a large multi-
plex inbred Algerian family and subsequently in three
other Maghreb families with the same mutation in the
TMEM126A gene, suggesting a founder effect. In these
family, some patients presented mild auditory alterations
and hypertrophic cardiopathy [51].
OPA8: One large family with a optic atrophy undistin-
guishable from that related to OPA1 was recently
described. In this family late-onset sensorineural hearing
loss, increases of central conduction times at somato-
sensory evoked potentials, and various cardiac abnor-
malities were also described in some patients [53].
DOA differential diagnosis with other hereditary optic
neuropathies
Leber Hereditary Optic Neuropathy (LHON) is the
major differential diagnosis for optic atrophy type 1
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quentially in both eyes, within six months. The acute
phase begins with blurring of central vision and color
desaturation. The central visual acuity deteriorates to
the level of counting fingers in up to 80% of cases, asso-
ciated with a large centrocecal scotoma. In few cases, in
particular in patients with the m.14484 G>A mutation,
visual acuity may partially improve over time. Males are
more commonly affected than females and women tend
to develop the disorder slightly later in life and may be
more severely affected, sometimes with associated mul-
tiple sclerosis like symptoms. Other neurologic abnor-
malities, such as a postural tremor or the loss of ankle
reflexes are also found. LHON is maternally inherited by
mutation in the mitochondrial genome, in most patients
(95% of cases) by one of the three mutations
m.11778G>A, m.14484T >C, and m.3460G>A [90].
Differential diagnosis between syndromic DOA
and other diseases
Wolfram syndrome Mutations in the WFS1 gene are
generally associated with optic atrophy as part of the
autosomal recessive Wolfram syndrome phenotype
(DIDMOAD, diabetes insipidus, diabetes mellitus, optic
atrophy, deafness) [91,92] or with autosomal dominant
progressive low-frequency sensori-neural hearing loss
that can be associated with DOA, with or without
impaired glucose regulation [93,94], supporting the no-
tion that mutations in WFS1 as well as in OPA1 may lead
to optic atrophy combined with hearing impairment.
Costeff syndrome Truncating mutations in OPA3 gene
are responsible for 3-methylglutaconic aciduria type 3, a
recessive neuro-ophthalmologic syndrome consisting of
early-onset bilateral optic atrophy and later-onset spasticity,
extra-pyramidal dysfunction, and cognitive deficit. Urinary
excretion of 3-methylglutaconic and 3-methylglutaric acids
is increased [52,95].
Charcot-Marie-Tooth type 2A2 (CMT2A) is a periph-
eral distal neuropathy with optic atrophy designated as
hereditary motor and sensory neuropathy type VI (HMSN
VI) [96]. HMSN VI families display subacute onset of
optic atrophy and subsequent slow recovery of visual acu-
ity in 60% of affected individuals. In each pedigree a dom-
inant mutation in the MFN2 gene coding the outer
mitochondrial dynamin mitofusin 2, was identified [97].
Recently a novel mutation inMFN2 as been described in a
patient with a DOAplus clinical presentation, featuring
also mtDNA deletions in the calf muscle [98].
Deafness-dystonia-optic neuronopathy syndrome
(DDON) is a disease associating slowly progressive
decreased visual acuity from optic atrophy beginningat about 20 years of age with neuro-sensorial hearing
impairment, slowly progressive dystonia or ataxia and de-
mentia beginning at about 40 years of age. Neurologic,
visual, and neuropsychiatric symptoms vary in degree of
severity and rate of progression [99]. As the inheritance is
X-linked, males are only affected, although females may
present mild hearing impairment and focal dystonia. The
DDON syndrome is linked to mutation in TIMM8A or to
a deletion at Xq22, also causing X-linked agammaglobu-
linemia due to the disruption of the BTK gene located
telomeric to TIMM8A [100].
Other inherited disorders of Oxidative Phosphorylation
Mitochondrial diseases featuring a defect in the respira-
tory chain affect about 1/4000 individuals. They include
clinical presentations with widely differing genetic origin
and phenotypic expression. Their clinical expression is
mainly neuromuscular and neurosensorial, but the major
physiological systems and functions may also be affected.
More than a hundred pathogenic mutations have been
described in mitochondrial DNA since 1988, and new
mutations are still regularly being reported. MtDNA
mutations may be secondary to the mutations of nuclear
genes encoding the proteins that ensure the mainten-
ance of mtDNA. Since 1995, more than 70 nuclear genes
have been involved in respiratory chain defects. The
clinical defects identified in DOAplus (deafness, per-
ipheral neuropathy, chronic external ophthalmoplegia,
myopathy, encephalopathy, multiple sclerosis-like syn-
dromes) are typical of those found in multisystemic
mitochondrial diseases that often themselves include
optic atrophy. Thus, facing a multisystemic mitochondrial
syndrome with optic atrophy it is important to check for
OPA1 mutations, but many other mitochondrial diseases
not related to OPA1 can also display a clinical presentation
similar to DOAplus, as recently evidenced by the discov-
ery of a singular mis-sense mutation in the MFN2 gene
leading to a DOAplus phenotype [98]. Interestingly, in a
few cases, the clinical presentations of OPA1 mutations
excluded optic nerve involvement [9,101], suggesting that
rare OPA1-associated diseases may tend towards clinical
phenotypes far removed from the initial description of
DOA.
Genetic counseling
DOA is inherited as an autosomal dominant trait. When
the causative mutation has been identified either in
OPA1 or OPA3 genes, it should be present in one of the
parents except in de novo cases, and will be transmitted
with a 50% chance to the proband sibs. When the causa-
tive mutation is not identified, genetic analysis can be
performed on the family if other members are affected,
in order to localize the locus responsible for the disease.
Nevertheless, in these latter cases, results might not
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main doubtful. Otherwise, when facing simplex pro-
band without known gene etiology, no genetic
counseling can be provided. Importantly, in isolated
cases, de novo mutations were frequently reported in
OPA1 gene, allowing consequently to provide advises
for family projections. In this respect, prenatal diag-
nosis for pregnancies at risk is feasible but remains
complicated when considering the incomplete pene-
trance and the markedly variable inter- and intra-
familial expressivity of DOA.
Antenatal diagnosis
The optimal time for determining genetic risk and sensi-
tizing future parents to genetic testing is obviously be-
fore pregnancy. If young adults are affected or at risk, it
will be appropriate to discuss the potential risk for their
offspring and the reproductive options, as pre-
implantation genetic diagnosis is available for families in
which the disease-causing mutation or locus has been
identified. Alternatively, prenatal genetic diagnosis for
pregnancies at risk is possible by analysis of DNA
extracted from fetal cells obtained by amniocentesis,
again when the disease-causing allele in the affected
family member has been identified.
Prenatal testing for DOA is controversial and uncom-
mon, especially since the disease does not affect intellec-
tual development or life span. Prenatal testing implies a
thorough discussion between the health care profes-
sionals and the involved parents.
Management including treatment
The management of DOA patient consists in regular
ophthalmologic examination, including measurement of
visual acuity, color vision, visual fields and OCT. To
date, no specific treatment exists, but low-vision aids in
patients with severely decreased visual acuity can be
beneficial. Avoiding tobacco and alcohol intake as well
as medications (antibiotics, antivirals) which can inter-
fere with mitochondrial metabolism can be additional
prophylactic measures.
Cochlear implants have been shown to restore a
marked improved audition in patients with syndromic
DOA with neurosensorial deafness [37].
Prognosis
In most cases, the diagnosis of DOA is established
before adulthood. Subsequent visual loss is mild, but
can at times worsen acutely, while spontaneous im-
provement is exceptionally rare. However, patients
may develop adaptative strategies, allowing them to
fixate within intact retinal regions and thus comply
with a normal familial and social life, although insertionin the professional life might be compromised by the
visual defect.
Patients with syndromic DOA will experience a
more severe visual defect that often will be followed
by audition impairment, which together will affect
their social communication early in adulthood. Add-
itional symptoms can occur later during the third or
fourth decade of life, and are believed to progress
slowly.
Unresolved questions and conclusions
Although OPA1, the major gene responsible for DOA
has now been discovered more than ten years ago, much
remains to be understood to explain the specificity of
the disease that focus first on the optic nerve integrity.
Indeed two major challenges are unanswered: the identi-
fication of the princeps mechanism that is affected in
DOA, and deciphering why mainly RGCs are degenerat-
ing in this disease. Answering both of these questions
should facilitate the future design of treatments.
The current absence of treatment for DOA raises a
tremendous challenge in testing therapeutic strategies
on the different available models, from cell lines to ani-
mals. It is probably not beyond reasonable hope to think
that in the next ten years, treatments will be found to re-
strain the RGCs loss in DOA.
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